Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Liposarcoma
ADR ID BADD_A07363
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.33      Soft tissue neoplasms malignant and unspecified
16.33.05      Liposarcomas malignant
16.33.05.001      Liposarcoma
15      Musculoskeletal and connective tissue disorders
15.09      Musculoskeletal and connective tissue neoplasms
15.09.03      Malignant musculoskeletal and connective tissue neoplasms
15.09.03.005      Liposarcoma
Description A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed) [MeSH]
MedDRA Code 10024627
MeSH ID D008080
ADR Severity Grade (FAERS) Not Available
ADR Severity Grade (CTCAE) Not Available
Synonym
Liposarcoma | Liposarcoma non-metastatic | Liposarcoma NOS | Liposarcoma stage unspecified | Liposarcomas | Liposarcoma, Dedifferentiated | Dedifferentiated Liposarcoma | Dedifferentiated Liposarcomas | Liposarcoma, Pleomorphic | Pleomorphic Liposarcoma | Pleomorphic Liposarcomas | Well Differentiated Liposarcoma | Well Differentiated Liposarcomas | Atypical Lipomatous Tumor | Atypical Lipomatous Tumors | Lipomatous Tumor, Atypical | Liposarcoma, Well Differentiated
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00551Cyclosporine--
BADD_D01253Lenalidomide0.000241%
BADD_D01687Pazopanib0.000112%
BADD_D02373Warfarin0.000028%
The 1th Page    1    Total 1 Pages